Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

QuEra Computing Releases a Groundbreaking Roadmap for Advanced Error-Corrected Quantum Computers, Pioneering the Next Frontier in Quantum Innovation 10-01-2024, 03:07

Nufarm Partners with KD Nutra on Plant-Based Omega-3 Portfolio Expansion 24-07-2024, 15:00